Advertisement

International Journal of Hematology

, Volume 103, Issue 3, pp 274–282 | Cite as

TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo

  • Somayeh Kalanaky
  • Maryam Hafizi
  • Sepideh Safari
  • Kazem Mousavizadeh
  • Mahboubeh Kabiri
  • Alireza Farsinejad
  • Saideh FakharzadehEmail author
  • Mohammad Hassan NazaranEmail author
Original Article

Abstract

Iron chelation therapy is an effective approach to the treatment of iron overload conditions, in which iron builds up to toxic levels in the body and may cause organ damage. Treatments using deferoxamine, deferasirox and deferiprone have been introduced and despite their disadvantages, they remain the first-line therapeutics in iron chelation therapy. Our study aimed to compare the effectiveness of the iron chelation agent TLc-A, a nano chelator synthetized based on the novel nanochelating technology, with deferoxamine. We found that TLc-A reduced iron overload in Caco2 cell line more efficiently than deferoxamine. In rats with iron overload, very low concentrations of TLc-A lowered serum iron level after only three injections of the nanochelator, while deferoxamine was unable to reduce iron level after the same number of injections. Compared with deferoxamine, TLc-A significantly increased urinary iron excretion and reduced hepatic iron content. The toxicity study showed that the intraperitoneal median lethal dose for TLc-A was at least two times higher than that for deferoxamine. In conclusion, our in vitro and in vivo studies indicate that the novel nano chelator compound, TLc-A, offers superior performance in iron reduction than the commercially available and widely used deferoxamine.

Keywords

TLc-A Deferoxamine Nanochelating Technology Iron overload Nano chelator 

Notes

Acknowledgments

All financial support was provided by the Department of Research and Development at the Sodour Ahrar Shargh Company. We are grateful to Etrat S Moghimi and Fakhrosadat Nasiri for their help in this project.

Compliance with ethical standards

Conflict of interest

The other authors report no conflicts of interest in this work.

References

  1. 1.
    MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10:997–1030.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 1977;50:433–9.PubMedGoogle Scholar
  3. 3.
    Breuer W, Greenberg E, Cabantchik ZI. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett. 1997;403:213–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol/Oncol Clin N Am. 2014;28:703–27.CrossRefGoogle Scholar
  5. 5.
    Mair SM, Weiss G. New pharmacological concepts for the treatment of iron overload disorders. Curr Med Chem. 2009;16:576–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Danjou F, Origa R, Anni F, Saba L, Cossa S, Podda G, et al. Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment. Blood Cells Mol Dis. 2013;51:142–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Angelucci E, Baronciani D, Lucarelli G, Baldassarri M, Galimberti M, Giardini C, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89:757–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today–prediction, prevention and management. Eur J Haematol. 2008;80:93–106.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassaemic patients. Expert Opin Pharmacother. 2003;4:1763–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–68.CrossRefPubMedGoogle Scholar
  11. 11.
    Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842–52.PubMedGoogle Scholar
  12. 12.
    Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28:894–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol. 2008;120:123–8.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007;109:5157–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005;1054:124–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Aslam N, Mettu P, Marsano-Obando LS, Martin A. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg-Pak: JCPSP. 2010;20:551–3.PubMedGoogle Scholar
  20. 20.
    Imran FS, Phatak P. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg-Pak: JCPSP. 2011;21:718 (author reply).PubMedGoogle Scholar
  21. 21.
    Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9:633–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Peters R. The nanopore connection to cell membrane unitary permeability. Traffic. 2005;6:199–204.CrossRefPubMedGoogle Scholar
  23. 23.
    Boyapalle S, Mohapatra S, Mohapatra S. Nanotechnology applications to HIV vaccines and microbicides. J Glob Infect Dis. 2012;4:62–8.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Controll Release: Off J Controll Release Soc. 2008;132:164–70.CrossRefGoogle Scholar
  25. 25.
    Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, et al. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine. 2013;31:2591–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, et al. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice. Int J Nanomed. 2014;9:3841–53.Google Scholar
  27. 27.
    Maghsoudi A, Fakharzadeh S, Hafizi M, Abbasi M, Kohram F, Sardab S, et al. Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity. Apoptosis Int J Program Cell Death. 2015;20:298–309.CrossRefGoogle Scholar
  28. 28.
    Nazaran MH. Chelate compounds. Google Patents US8288587; 2012.Google Scholar
  29. 29.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. Hemoglobin. 2011;35:206–16.CrossRefPubMedGoogle Scholar
  30. 30.
    Spraul CW, Schicketanz C. Lang GE [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis]. Klin Monatsbl Augenheilkd. 1996;209:31–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Porter JB, Taher AT, Cappellini MD, Vichinsky EP. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008;32:601–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Kontoghiorghes GJ. Hemoglobin. 2008;32(1–2):1–15.CrossRefPubMedGoogle Scholar
  33. 33.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25:725–42.CrossRefPubMedGoogle Scholar
  34. 34.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E. Recent developments in iron chelation therapy. Klin Padiatr. 2007;219:158–65.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol. 2010;610:123–44.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Bonda DJ, Liu G, Men P, Perry G, Smith MA, Zhu X. Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming! CNS Neurol Disord: Drug Targets. 2012;11:81–5.CrossRefGoogle Scholar
  37. 37.
    Liu G, Men P, Perry G, Smith MA. Chapter 5—Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res. 2009;180:97–108.CrossRefPubMedGoogle Scholar
  38. 38.
    Seshadri R, Colebatch JH, Fisher R. Urinary iron excretion in thalassaemia after desferrioxamine administration. Arch Dis Child. 1974;49:195–9.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I. Evaluation of liver fibrosis in patients with thalassemia: the important role of hyaluronic acid. Blood Cells Mol Dis. 2010;45:215–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Hodges YK, Weinberger HD, Stephens J, Horwitz MA, Horwitz LD. Desferri-exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron. Transl Res: J Lab Clin Med. 2006;148:63–71.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2016

Authors and Affiliations

  • Somayeh Kalanaky
    • 1
  • Maryam Hafizi
    • 1
    • 2
  • Sepideh Safari
    • 1
  • Kazem Mousavizadeh
    • 3
  • Mahboubeh Kabiri
    • 4
  • Alireza Farsinejad
    • 5
  • Saideh Fakharzadeh
    • 1
    Email author
  • Mohammad Hassan Nazaran
    • 1
    Email author
  1. 1.Department of Research and DevelopmentSodour Ahrar Shargh CompanyTehranIran
  2. 2.Cancer Research CentreShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Cellular and Molecular Research CenterIran University of Medical SciencesTehranIran
  4. 4.Department of Biotechnology, College of ScienceUniversity of TehranTehranIran
  5. 5.Department of Laboratory Science, Faculty of Allied MedicineKerman University of Medical SciencesKermanIran

Personalised recommendations